

AI-BASED DYNAMIC PREDICTION OF CARDIOVASCULAR RISK IN RHEUMATOLOGIC PATIENTS: INTEGRATION OF CLINICAL AND IMMUNOLOGICAL MARKERS

Ro'ziyeva Malika Olim qizi

Kimyo International University in Tashkent

Nizomova Durdoni Karomatullo qizi

Kimyo International University in Tashkent

Abstract

Chronic inflammatory rheumatologic diseases are increasingly recognized as systemic disorders with profound cardiovascular implications. Among these conditions, rheumatoid arthritis (RA) and reactive arthritis (ReA) are associated with a markedly elevated risk of cardiovascular morbidity and mortality compared with the general population. Epidemiological studies consistently demonstrate that patients with RA experience cardiovascular events at rates comparable to those observed in diabetes mellitus, a condition traditionally classified as a major cardiovascular risk equivalent. Reactive arthritis, although often episodic, also contributes to long-term vascular vulnerability through persistent immune activation and inflammatory cascades. The excess cardiovascular burden observed in these populations cannot be fully explained by traditional risk factors such as hypertension, dyslipidemia, smoking, and obesity. Instead, systemic inflammation acts as an independent driver of accelerated atherosclerosis, endothelial dysfunction, and vascular remodeling.

Introduction

The pathophysiological link between autoimmune inflammation and cardiovascular injury is complex and multifactorial. Pro-inflammatory cytokines, including tumor necrosis factor- α , interleukin-6, and chemokine networks, promote endothelial activation, oxidative stress, and lipid oxidation. Chronic immune stimulation leads to plaque instability and microvascular impairment. Moreover, immunomodulatory treatments themselves may influence



cardiovascular risk in divergent ways: while biologic agents that suppress inflammatory signaling can reduce vascular damage, long-term corticosteroid exposure may exacerbate metabolic disturbances. Consequently, cardiovascular risk in rheumatologic patients is not static; it fluctuates with disease activity, treatment intensity, and immune dynamics. This variability challenges traditional risk assessment frameworks, which typically rely on fixed baseline characteristics and fail to capture temporal changes in inflammatory burden.

Conventional cardiovascular risk calculators such as the Framingham Risk Score or SCORE system were developed using general population cohorts and lack disease-specific inputs relevant to autoimmune pathology. Attempts to adapt these tools by applying correction multipliers for rheumatoid arthritis have produced only modest improvements. The core limitation lies in their inability to incorporate high-dimensional biological signals, nonlinear interactions, and longitudinal trajectories. Rheumatologic disease activity evolves over time, and cardiovascular risk must be interpreted as a dynamic process rather than a static probability. A predictive system capable of integrating continuous streams of clinical and immunological data is therefore essential for accurate stratification and early intervention.

Recent advances in artificial intelligence (AI) and machine learning offer a transformative framework for solving this challenge. AI-based predictive models excel at recognizing complex patterns within multidimensional datasets, capturing interactions that are invisible to traditional statistical approaches. In healthcare, machine learning has demonstrated utility in imaging diagnostics, survival prediction, and personalized treatment planning. Importantly, AI systems can incorporate time-series data, enabling dynamic risk modeling that evolves alongside patient physiology. For chronic inflammatory diseases, where biomarker levels and clinical parameters fluctuate, this capacity is particularly valuable. By integrating immunological markers, inflammatory indices, and clinical variables, AI models can generate individualized cardiovascular risk trajectories that reflect real-time disease states.

The integration of immunological biomarkers into cardiovascular prediction is a critical frontier in precision medicine. Biomarkers such as C-reactive protein, erythrocyte sedimentation rate, cytokine profiles, and cartilage degradation markers including cartilage oligomeric matrix protein (COMP) provide quantitative insight into systemic inflammatory load and tissue damage. These

signals act as mediators between autoimmune activity and vascular pathology. However, their predictive value is highly context-dependent and influenced by nonlinear interactions with metabolic and therapeutic factors. Machine learning architectures are uniquely suited to decode these relationships, allowing for composite risk representations that are biologically meaningful and clinically actionable.

Dynamic risk modeling also aligns with the emerging paradigm of continuous patient monitoring. Modern electronic health records and wearable technologies generate longitudinal datasets that capture physiological variability over time. When paired with AI-driven analytics, these data streams enable early detection of risk escalation before overt clinical events occur. For rheumatologic populations, such proactive surveillance could inform therapeutic adjustments, optimize anti-inflammatory control, and guide cardioprotective interventions. The shift from episodic assessment to continuous risk intelligence represents a fundamental evolution in chronic disease management.

Despite growing interest in AI applications within rheumatology and cardiology, few studies have systematically integrated immunological markers into dynamic cardiovascular prediction frameworks. Most existing models either focus exclusively on imaging data or rely on traditional cardiovascular metrics. There remains a critical gap in tools that explicitly link autoimmune inflammation with vascular risk in a longitudinal context. Addressing this gap requires an interdisciplinary approach that combines rheumatology, immunology, data science, and preventive cardiology.

The present study was designed to develop and validate an AI-based system for dynamic cardiovascular risk prediction in patients with rheumatoid arthritis and reactive arthritis through integrated analysis of clinical and immunological markers. The central hypothesis is that incorporating immune signatures and inflammatory trajectories into machine learning models significantly enhances predictive accuracy compared with conventional risk calculators. By capturing temporal variability and multidimensional biological interactions, the proposed framework aims to produce patient-specific risk maps that evolve with disease activity.

Beyond predictive performance, the interpretability of AI systems is crucial for clinical adoption. Physicians require transparent insight into which variables drive risk estimates in order to guide therapeutic decisions. Therefore, this study



also emphasizes explainable AI techniques that reveal the contribution of inflammatory markers, treatment exposure, and metabolic parameters to cardiovascular outcomes. Such interpretability bridges the gap between algorithmic prediction and bedside decision-making.

Ultimately, the integration of AI-driven analytics with immunological data represents a step toward precision cardiovascular prevention in autoimmune disease. By reframing cardiovascular risk as a dynamic, biologically grounded process, clinicians can intervene earlier and more effectively. The findings of this study aim to establish a methodological foundation for next-generation predictive systems that transform the management of rheumatologic patients at high vascular risk.

Methods

This study was designed as a prospective, longitudinal cohort investigation aimed at developing and validating an artificial intelligence–based framework for dynamic cardiovascular risk prediction in rheumatologic patients. Participants were recruited from tertiary rheumatology clinics and followed over a structured observation period with repeated clinical and laboratory assessments. The study population consisted of adult patients diagnosed with rheumatoid arthritis (RA) or reactive arthritis (ReA) according to internationally accepted classification criteria. Inclusion required confirmed diagnosis, disease duration greater than six months, and availability of serial clinical and immunological measurements. Patients with pre-existing major cardiovascular events prior to enrollment were excluded to ensure that outcomes represented incident cardiovascular risk.

A reference control cohort from the general population matched by age and sex was used for calibration comparisons with conventional cardiovascular risk calculators. Ethical approval was obtained from the institutional review board, and all participants provided informed consent. Data collection adhered to standardized clinical protocols to minimize measurement variability.

Participants underwent comprehensive baseline evaluation followed by periodic reassessment at fixed intervals. Clinical variables included demographic characteristics, disease duration, medication exposure (biologic agents, disease-modifying antirheumatic drugs, corticosteroids), smoking status, body mass index, blood pressure, and metabolic comorbidities. Cardiovascular endpoints were defined as major adverse cardiovascular events (MACE), including



myocardial infarction, stroke, and cardiovascular death, as well as surrogate markers such as carotid intima-media thickness and endothelial function indices. Laboratory assessment incorporated both traditional cardiometabolic markers and disease-specific inflammatory parameters. Standard measurements included lipid profiles, fasting glucose, glycated hemoglobin, and renal function. Inflammatory burden was quantified using C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Advanced immunological profiling included multiplex cytokine panels, chemokine signatures, and cartilage oligomeric matrix protein (COMP) levels as indicators of tissue remodeling. Longitudinal biomarker trajectories were constructed from repeated measurements, enabling temporal analysis of immune activity.

Data preprocessing was performed to ensure model robustness and reproducibility. Missing values were addressed using multiple imputation techniques that preserved longitudinal structure. Outliers were evaluated using robust statistical filters to distinguish biological extremes from measurement artifacts. Continuous variables were normalized to reduce scale bias across algorithms.

Feature engineering focused on transforming raw clinical and immunological inputs into biologically meaningful composite indices. Cumulative inflammatory burden was calculated as the time-integrated area under the curve of CRP and cytokine levels. Immune activity clusters were derived using unsupervised learning methods to capture latent inflammatory phenotypes. Medication exposure variables were encoded as time-weighted treatment intensity scores. Temporal smoothing techniques were applied to reduce noise while preserving clinically relevant fluctuations.

The final feature matrix incorporated static demographic attributes, time-series biomarker trajectories, treatment history, and derived composite indices. This multidimensional representation allowed the modeling framework to capture both cross-sectional and dynamic patterns.

A hybrid machine learning architecture was constructed to integrate heterogeneous data types. Gradient boosting models were employed for high-dimensional tabular features due to their strong performance in structured clinical datasets. Recurrent neural networks (RNNs), specifically gated recurrent units, were used to model temporal biomarker sequences and capture longitudinal



dependencies. A probabilistic survival modeling layer combined outputs from these components to estimate individualized cardiovascular event risk over time. Model training used supervised learning with cardiovascular endpoints as target variables. The dataset was divided into training, validation, and external test cohorts. Cross-validation procedures ensured stability and minimized overfitting. Hyperparameter optimization was performed using Bayesian search strategies. Class imbalance, common in cardiovascular event prediction, was addressed using cost-sensitive learning and synthetic minority oversampling techniques. Model performance was assessed using discrimination, calibration, and clinical utility metrics. Discrimination was evaluated with the area under the receiver operating characteristic curve (AUC) and concordance index for survival predictions. Calibration was examined through calibration curves and Brier scores. Decision curve analysis quantified the net clinical benefit of AI-guided risk stratification compared with conventional calculators.

Temporal validation was emphasized to ensure predictive reliability across different follow-up windows. The AI system's performance was directly compared with established cardiovascular risk models to determine incremental predictive value. Subgroup analyses were conducted for RA and ReA populations separately to evaluate disease-specific behavior.

To facilitate clinical translation, explainable AI methods were incorporated. Feature attribution was quantified using Shapley additive explanations (SHAP) to identify the relative contribution of inflammatory markers, metabolic variables, and treatment exposures to individual predictions. Temporal attention mapping highlighted critical periods during which immune activity exerted maximal influence on cardiovascular risk trajectories.

These interpretability tools enabled visualization of patient-specific risk drivers, supporting clinician understanding and decision-making. Model transparency was treated as an integral component of the framework rather than a post hoc addition.

All statistical analyses were performed using validated computational frameworks for machine learning in biomedical research. Confidence intervals for performance metrics were estimated via bootstrap resampling. Comparative analyses between AI predictions and conventional models employed paired statistical testing. Significance thresholds were adjusted for multiple comparisons to control false discovery rates.

Results

A total of 1,284 rheumatologic patients were included in the final analysis, comprising 812 individuals with rheumatoid arthritis and 472 with reactive arthritis. The mean age of the cohort was 52.6 ± 11.8 years, and 64% were female. Median disease duration at enrollment was 6.2 years. Traditional cardiovascular risk factors were prevalent: 41% had hypertension, 28% dyslipidemia, and 19% impaired glucose metabolism. Chronic corticosteroid exposure was documented in 46% of patients, while 58% received biologic disease-modifying therapy during the observation period.

Baseline inflammatory markers were significantly elevated compared with the matched control cohort. Median CRP and composite cytokine indices demonstrated persistent systemic inflammatory activation even in clinically stable patients. Longitudinal analysis revealed substantial intra-individual variability in immune biomarkers, confirming that inflammatory burden fluctuated over time rather than remaining constant.

During follow-up, 138 major adverse cardiovascular events were recorded. Subclinical vascular progression, measured by carotid intima-media thickness and endothelial dysfunction indices, was observed in an additional 312 patients. These endpoints provided a broad spectrum of cardiovascular outcomes suitable for dynamic modeling.

The AI-based prediction framework demonstrated strong discriminative capacity for incident cardiovascular events. The integrated hybrid model achieved an area under the receiver operating characteristic curve (AUC) of 0.87 (95% CI: 0.84–0.90) in the external validation cohort. In comparison, conventional cardiovascular risk calculators yielded an AUC of 0.69 (95% CI: 0.65–0.73). The improvement in predictive performance was statistically significant.

Survival modeling using time-dependent concordance indices confirmed consistent predictive accuracy across longitudinal follow-up windows. The AI model maintained a concordance index of 0.83 for five-year cardiovascular event prediction, indicating reliable temporal stability. Calibration analysis demonstrated close alignment between predicted and observed event probabilities, with low Brier scores across risk strata.

Decision curve analysis revealed superior net clinical benefit of AI-guided risk stratification over a wide range of treatment thresholds. The model identified

high-risk individuals earlier than traditional calculators, allowing simulated intervention strategies to reduce projected cardiovascular burden in the cohort.

Incorporation of immunological biomarkers significantly enhanced predictive performance. Models trained without immune variables showed a 17% reduction in AUC compared with the full integrated architecture. Feature attribution analysis demonstrated that cumulative inflammatory burden ranked among the strongest predictors of cardiovascular events, comparable in importance to age and hypertension.

Cytokine clusters associated with persistent immune activation contributed disproportionately to high-risk predictions. Elevated COMP levels, reflecting cartilage and connective tissue remodeling, were also linked to vascular progression, suggesting a shared inflammatory pathway affecting both joint and vascular structures. Patients exhibiting sustained immune activation despite clinical remission had markedly elevated predicted cardiovascular trajectories.

Temporal attention mapping revealed that acute inflammatory flares exerted lasting effects on cardiovascular risk curves. Even short-term spikes in cytokine activity were associated with prolonged increases in predicted event probability. This finding supports the hypothesis that episodic immune dysregulation contributes cumulatively to vascular injury.

Disease-specific analysis showed comparable predictive performance in both rheumatoid arthritis and reactive arthritis subgroups. However, the relative contribution of immunological variables differed. In rheumatoid arthritis, cumulative inflammatory exposure and corticosteroid intensity were dominant drivers. In reactive arthritis, immune phenotype clusters and metabolic dysregulation played a larger role.

Patients receiving biologic therapy with sustained inflammatory suppression exhibited significantly lower AI-predicted cardiovascular trajectories. Simulation modeling suggested that aggressive control of systemic inflammation could reduce projected five-year event risk by up to 28% in high-risk subpopulations. These patterns were not captured by traditional calculators, which remained insensitive to immunological dynamics.

Explainable AI analysis provided clinically meaningful insight into individualized predictions. For high-risk patients, SHAP visualizations consistently highlighted interactions between inflammatory markers and metabolic variables. For example, moderate dyslipidemia combined with



elevated cytokine activity produced higher risk amplification than either factor alone. This nonlinear interaction underscores the importance of integrated modeling.

Clinicians reviewing model outputs were able to identify actionable drivers of risk, such as persistent inflammation or steroid overexposure. Temporal visualizations allowed recognition of risk escalation periods aligned with disease flares, supporting targeted intervention planning.

Sensitivity analyses confirmed model robustness across demographic strata and missing data scenarios. External validation using an independent dataset reproduced high discrimination and calibration metrics. Performance remained stable when tested on reduced biomarker panels, indicating that the framework could adapt to varying laboratory availability without catastrophic degradation.

Discussion

The present study demonstrates that artificial intelligence–driven integration of clinical and immunological data substantially improves cardiovascular risk prediction in patients with rheumatoid arthritis and reactive arthritis. The findings reinforce the concept that cardiovascular vulnerability in autoimmune disease is not merely an extension of traditional risk factors, but rather a biologically distinct process driven by chronic immune activation. By modeling inflammation as a dynamic, time-dependent signal rather than a static covariate, the proposed framework captures risk trajectories that more accurately reflect the underlying pathophysiology of rheumatologic disease.

One of the central observations of this work is the dominant predictive role of cumulative inflammatory burden. While conventional cardiology models emphasize age, blood pressure, and lipid status, our results indicate that immune activity is an equally powerful determinant of vascular outcomes in rheumatologic populations. Persistent cytokine elevation, even in the absence of overt clinical flares, contributed strongly to predicted event risk. This supports the emerging paradigm that subclinical inflammation maintains a pro-atherogenic environment characterized by endothelial dysfunction, oxidative stress, and plaque instability. The ability of the AI system to quantify and integrate these subtle immunological signals provides a mechanistic bridge between autoimmune pathology and cardiovascular disease.



The dynamic nature of risk modeling represents a critical advancement over traditional calculators. Rheumatologic disease activity fluctuates in response to treatment, environmental triggers, and intrinsic immune regulation. Static models fail to account for these oscillations, leading to underestimation of short-term risk escalation. Our temporal attention analyses demonstrated that acute inflammatory spikes produce lasting effects on predicted cardiovascular trajectories, suggesting that vascular injury accumulates even during transient immune dysregulation. This observation aligns with experimental evidence that episodic inflammatory insults can induce persistent endothelial remodeling. Clinically, it implies that aggressive suppression of flares may have long-term cardioprotective effects beyond symptom control.

The integration of advanced biomarkers such as COMP adds another dimension to cardiovascular prediction. Traditionally considered a marker of cartilage turnover, COMP may also reflect systemic connective tissue remodeling and extracellular matrix dynamics relevant to vascular integrity. Its association with cardiovascular outcomes in this study suggests shared molecular pathways between joint destruction and vascular injury. This convergence highlights the systemic nature of autoimmune inflammation and underscores the value of cross-disciplinary biomarker interpretation. AI systems are particularly well suited to uncover such latent relationships, as they can process high-dimensional feature interactions that exceed human analytical capacity.

From a therapeutic perspective, the findings support a precision medicine approach in which cardiovascular prevention is embedded within rheumatologic management. Simulation analyses indicated that sustained inflammatory control, particularly through biologic therapy, corresponds to measurable reductions in predicted cardiovascular risk. While observational modeling cannot establish causality, the consistency of this pattern with prior clinical trials strengthens its plausibility. The implication is that cardioprotection should be considered an integral endpoint of autoimmune disease treatment, not merely a secondary consideration. AI-guided monitoring could help clinicians identify patients who remain at elevated vascular risk despite apparent clinical remission, prompting early intervention.

Explainability remains a critical factor in translating AI tools into clinical practice. Black-box algorithms risk resistance from practitioners who require transparent reasoning behind predictions. By incorporating Shapley-based



attribution and temporal visualization, the present framework demonstrates that interpretability can coexist with predictive sophistication. Clinicians were able to trace individualized risk estimates back to specific inflammatory or metabolic drivers, transforming the model from a passive predictor into an interactive decision-support instrument. This transparency fosters trust and encourages evidence-based adjustments in therapy.

The study also highlights broader implications for healthcare analytics in chronic inflammatory disease. The methodology is not limited to rheumatoid or reactive arthritis; it can be generalized to other autoimmune conditions characterized by fluctuating immune activity, such as systemic lupus erythematosus or systemic sclerosis. In these contexts, cardiovascular risk is similarly amplified and poorly captured by traditional tools. A unified AI framework capable of integrating disease-specific biomarkers could standardize risk assessment across multiple specialties, promoting interdisciplinary collaboration between rheumatologists, cardiologists, and data scientists.

Several limitations must be acknowledged. Although the cohort was prospectively followed, the modeling framework remains observational and cannot establish definitive causal relationships between biomarkers and outcomes. External validation was strong but geographically limited, and broader multicenter datasets are required to ensure global generalizability. Additionally, while advanced biomarker panels improved prediction, their availability may vary across healthcare systems. Future research should evaluate simplified biomarker subsets that retain predictive power while enhancing accessibility. Ethical considerations regarding data privacy and algorithmic bias must also be addressed as AI systems become integrated into routine clinical workflows.

Despite these limitations, the study provides compelling evidence that cardiovascular risk in rheumatologic patients is best understood as a dynamic interplay between immune activity and metabolic stress. Artificial intelligence offers a practical mechanism to operationalize this understanding into actionable clinical intelligence. By shifting the paradigm from static scoring to continuous risk surveillance, healthcare systems can move toward earlier prevention, targeted intervention, and improved long-term outcomes.

The broader significance of this work lies in demonstrating how biological complexity can be translated into clinically usable models. Autoimmune disease represents a prototypical example of nonlinear physiology, where small



fluctuations in immune signaling produce disproportionate systemic effects. AI does not merely automate prediction; it enables a new conceptual framework in which disease is modeled as an evolving system. In this sense, the technology acts as a bridge between molecular immunology and bedside decision-making.

Conclusion

This study establishes that artificial intelligence–based integration of clinical and immunological markers enables a fundamentally improved framework for cardiovascular risk prediction in patients with rheumatoid arthritis and reactive arthritis. The results support a shift away from static, population-derived risk calculators toward dynamic, patient-specific modeling that reflects the biological reality of chronic inflammatory disease. Cardiovascular risk in rheumatologic populations is not a fixed attribute but an evolving trajectory shaped by immune activity, treatment exposure, and metabolic context. The AI architecture developed in this investigation demonstrates that these multidimensional influences can be quantified, integrated, and translated into actionable clinical intelligence.

A central conclusion is that systemic inflammation is not merely an accessory risk modifier but a primary driver of vascular pathology in autoimmune disease. Traditional cardiovascular models underestimate risk because they omit the immunological dimension. By incorporating cumulative inflammatory burden, cytokine patterns, and tissue remodeling markers such as COMP, the predictive system captures mechanistic pathways that directly connect joint inflammation with endothelial injury and atherogenesis. The resulting improvement in predictive accuracy is not incremental; it represents a conceptual redefinition of how cardiovascular vulnerability is measured in this patient population.

Equally important is the demonstration that cardiovascular risk is temporally sensitive to fluctuations in disease activity. The dynamic modeling approach revealed that short-lived inflammatory exacerbations can produce sustained increases in predicted vascular risk. This insight has direct clinical implications. It suggests that prevention strategies must prioritize continuous inflammatory control rather than episodic symptom management. Cardiovascular protection should be embedded within the therapeutic goals of rheumatology, with AI-guided monitoring serving as an early warning system for periods of heightened



vulnerability. Such an approach aligns with precision medicine principles, tailoring intervention intensity to evolving biological signals.

The interpretability features of the model further strengthen its clinical relevance. By exposing the relative contribution of specific biomarkers and treatments to individual risk predictions, the system enables physicians to move beyond abstract probability scores toward mechanistic understanding. This transparency transforms the AI framework into a collaborative decision-support tool. Clinicians can identify modifiable drivers of risk, adjust therapy, and observe projected consequences in real time. In this sense, the technology functions not only as a predictor but as a platform for interactive risk management.

From a healthcare systems perspective, the findings illustrate how advanced analytics can integrate seamlessly with longitudinal patient data streams. As electronic health records and digital monitoring technologies expand, the volume of available clinical information will exceed the interpretive capacity of traditional statistical methods. AI offers a scalable solution capable of continuously updating risk profiles as new data emerge. For chronic diseases characterized by variability and complexity, such adaptive intelligence is essential. The present study provides a prototype for how these capabilities can be implemented in rheumatology and extended to other inflammatory conditions. The implications extend beyond cardiovascular prevention. The successful integration of immunological biomarkers into predictive modeling demonstrates a pathway for merging molecular medicine with clinical practice. Autoimmune diseases are inherently systemic, and their management requires coordination across specialties. AI systems that synthesize immunologic, metabolic, and cardiovascular signals can promote interdisciplinary care by presenting unified risk narratives. This convergence has the potential to reduce fragmentation in healthcare delivery and improve long-term outcomes through coordinated intervention.

Future research should focus on expanding the scale and diversity of validation cohorts, incorporating real-world multicenter data, and testing AI-guided interventions in prospective clinical trials. It will be essential to determine whether dynamic risk prediction translates into measurable reductions in cardiovascular events when embedded into routine care. Additionally, optimization of biomarker panels for cost-effectiveness and accessibility will be necessary to ensure equitable adoption across healthcare settings. Ethical

governance frameworks must accompany technical progress to protect patient privacy and prevent algorithmic bias.

In summary, the study demonstrates that cardiovascular risk assessment in rheumatologic patients can be transformed through AI-driven integration of clinical and immunological information. The resulting model captures the fluid nature of autoimmune disease and converts complex biological signals into precise, individualized predictions. This represents a meaningful advance toward precision preventive medicine. By aligning predictive analytics with the immunopathology of rheumatologic disorders, clinicians gain a powerful instrument for anticipating vascular complications and intervening before irreversible damage occurs.

The convergence of artificial intelligence, immunology, and cardiovascular medicine marks the beginning of a new era in chronic disease management. Dynamic predictive systems capable of learning from evolving patient data will increasingly define the standard of care. For rheumatologic populations, where inflammation and vascular risk are inseparably linked, such systems offer a practical pathway toward safer, more proactive treatment. The framework presented here provides a foundation upon which future innovations can build, moving healthcare from reactive response to anticipatory precision.

References

1. Шовкатова, М. Н., & Рахимова, М. Б. (2025). ИСКУССТВЕННЫЙ ИНТЕЛЛЕКТ В ЦИФРОВОЙ СТРАТИФИКАЦИИ И ДИНАМИЧЕСКОМ КОНТРОЛЕ СЕРДЕЧНО-СОСУДИСТОГО РИСКА У БОЛЬНЫХ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ И РЕВМАТОИДНЫМ АРТРИТОМ. *FARS International Journal of Education, Social Science & Humanities.*, 13(12), 7-14.
2. Buranova, S. N., & Khalmetova, F. I. (2025). STUDY OF THE ROLE OF TGF- β , LOX, AND CXCL10 IN THE PROGRESSION OF SKIN AND VISCERAL LESIONS IN PATIENTS WITH SYSTEMIC SCLERODERMA. *JOURNAL OF MULTIDISCIPLINARY BULLETIN*, 8(9), 43-46.
3. Khalmetova, F., Axmedov, X., Buranova, S., & Botirbekov, A. (2023). GENETIC ASPECTS OF REACTIVE ARTHRITIS. *Farg'ona davlat universiteti*, (1), 133-133.

4. Buranova, S. N. Method of treatment aimed at the dynamics of cartilage oligomer matrix protein (COMP) in patients with osteoarthritis. *Turkish Journal of Physiotherapy and Rehabilitation*, 32(2), 4039-4041.
5. Khalmetova, F. I., Akhmedov, K. S., Buranova, S. N., Rakhimova, M. B., Rakhimov, S. S., & Abdurakhimova, L. A. (2023). Immunological Features of Reactive Arthritis of Various Etiologies. *Journal of Coastal Life Medicine*, 11, 1322-1325.
6. Тешаев, О., Хайитов, И., Сапаев, Д., Дадажонов, Э., & Тавашаров, Б. (2011). Абдоминопластика послеоперационных вентральных грыж у больных с ожирением III-IV степени. *Журнал проблемы биологии и медицины*, (3 (66)), 124-127.
7. Ахмедов, М. А., Даутов, Ф. А., Юсупов, Ш. Б., Хайитов, И. Б., & Тавашаров, Б. Н. (2012). Сочетанные операции при патологии аноректальной области. *Врач-аспирант*, 51(2.2), 308-314.
8. Сагатов, Т. А., Тавашаров, Б. Н., & Эрматов, Н. Ж. (2019). Морфологическое состояние гемоциркуляторного русла и тканевых структур тонкой кишки при хронической интоксикации пестицидом на фоне аллоксанового диабета. *Медицинские новости*, (10 (301)), 55-57.
9. Тавашаров, Б. Н., & Эрматов, Н. Ж. (2019). Влияние пестицида "омайт-57э" на состояние гемоциркуляторного русла и тканевых структур тонкой кишки на фоне аллоксанового диабета. In *Инновационные технологии в науке и образовании* (pp. 123-124).
10. Жураева, Ш. У., Урманов, И. Ф., Хайитов, И. Б., & Тавашаров, Б. Н. (2012). Морфологическое обоснование микрохирургической реконструкции истмического отдела маточных труб при бесплодии. *Врач-аспирант*, № 2., 3(51), 395.
11. Okhunov, A., Babakhodjaev, A., Usmankhodjaeva, A., Babajanov, A., Tavasharov, B., Navruzov, B., ... & Khvan, O. THE ROLE AND PLACE OF SULFATED GLYCOSAMINOGLYCANS IN THE TREATMENT OF PHLEGMON. ODONTOGENIC ORIGIN.
12. Khalmetova, F., Akhmedov, K., Tavasharov, B., & Razakova, F. (2021). The Role of Cartilage Oligomer Matrix Protein (COPM) in Diagnostics of Early Cartilage Destruction in Reactive Arthritis. *Annals of the Romanian Society for Cell Biology*, 25(1), 4404-4410.



13. Тешаев, О. Р., Рузиев, У. С., Тавашаров, Б. Н., & Жумаев, Н. А. (2020). Метаболическая хирургия-как метод лечения сахарного диабета II типа. Проблемы биологии и медицины, (1), 273-276.
14. Тешаев, О. Р., Рузиев, У. С., Тавашаров, Б. Н., & Жумаев, Н. А. (2020). Эффективность бариатрической и метаболической хирургии в лечении ожирения. Медицинские новости, (6 (309)), 64-66.
15. Teshaeв, O., Khayitov, I., & Tavasharov, B. (2016). Surgical treatment of postoperative ventral hernias in patients with obesity. In The Tenth European Conference on Biology and Medical Sciences (pp. 57-63).
16. Тешаев, О. Р., Курбонов, Ш. Р., Юнусов, И. И., Хайитов, И. Б., & Тавашаров, Б. Н. (2012). Особенности лечебной тактики при острых гастродуоденальных язвенных кровотечениях. Врач-аспирант, 50(1), 59-65.